Vascular Injury and Thrombotic Potential: A Note of Caution About Recombinant Factor VIIa
Postoperative hemorrhage following cardiac surgery increases morbidity, mortality, and costs. Several case reports have described the successful use of recombinant factor VIIa to decrease or stop bleeding in patients undergoing cardiac surgery. The mechanism of action of recombinant factor VIIa is t...
Gespeichert in:
| Veröffentlicht in: | Seminars in cardiothoracic and vascular anesthesia 2007-12, Vol.11 (4), p.261-264 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 264 |
|---|---|
| container_issue | 4 |
| container_start_page | 261 |
| container_title | Seminars in cardiothoracic and vascular anesthesia |
| container_volume | 11 |
| creator | Mazer, C. David Leong-Poi, Howard Mahoney, James Latter, David Strauss, Bradley H. Teitel, Jerome M. |
| description | Postoperative hemorrhage following cardiac surgery increases morbidity, mortality, and costs. Several case reports have described the successful use of recombinant factor VIIa to decrease or stop bleeding in patients undergoing cardiac surgery. The mechanism of action of recombinant factor VIIa is thought to be increased site-specific thrombin generation by tissue factor—mediated activation of coagulation or from activated platelets. However, there have also been many reports of thrombotic complications after recombinant factor VIIa administration. Randomized clinical trials and further laboratory studies should help better clarify the efficacy, safety, cost-effectiveness, and optimal dosing of recombinant factor VIIa in the cardiac surgical setting. |
| doi_str_mv | 10.1177/1089253207311357 |
| format | Article |
| fullrecord | <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1177_1089253207311357</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1089253207311357</sage_id><sourcerecordid>10.1177_1089253207311357</sourcerecordid><originalsourceid>FETCH-LOGICAL-c335t-b531f56c64d024fcc3800cec2a7895824df39dad58f5b88dd04fb11cd3b49f453</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlbvniR_YDWTbLpZb6XYulBUpBY8LfnY6JY2KUn20H_vlhYEwdPM8H7APAjdArkHKIoHIKKknFFSMADGizM0hDInGefl-Lzfezk76AN0FeOaEEoosEs0AEELAqIcos-VjLrbyIArt-7CHktn8PI7-K3yqdX4zafGpVZuHvEEv_QH9hZPZZda7_BE-S7h90b37tZJl_BM6uQDXlWVvEYXVm5ic3OaI_Qxe1pOn7PF67yaThaZZoynTHEGlo_1ODeE5lZrJgjRjaayECUXNDeWlUYaLixXQhhDcqsAtGEqL23O2QiRY68OPsbQ2HoX2q0M-xpIfaBU_6XUR-6OkV2nto35DZyw9IbsaIjyq6nXvguuf-H_wh9O_m6q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Vascular Injury and Thrombotic Potential: A Note of Caution About Recombinant Factor VIIa</title><source>MEDLINE</source><source>SAGE Journals</source><creator>Mazer, C. David ; Leong-Poi, Howard ; Mahoney, James ; Latter, David ; Strauss, Bradley H. ; Teitel, Jerome M.</creator><creatorcontrib>Mazer, C. David ; Leong-Poi, Howard ; Mahoney, James ; Latter, David ; Strauss, Bradley H. ; Teitel, Jerome M.</creatorcontrib><description>Postoperative hemorrhage following cardiac surgery increases morbidity, mortality, and costs. Several case reports have described the successful use of recombinant factor VIIa to decrease or stop bleeding in patients undergoing cardiac surgery. The mechanism of action of recombinant factor VIIa is thought to be increased site-specific thrombin generation by tissue factor—mediated activation of coagulation or from activated platelets. However, there have also been many reports of thrombotic complications after recombinant factor VIIa administration. Randomized clinical trials and further laboratory studies should help better clarify the efficacy, safety, cost-effectiveness, and optimal dosing of recombinant factor VIIa in the cardiac surgical setting.</description><identifier>ISSN: 1089-2532</identifier><identifier>EISSN: 1940-5596</identifier><identifier>DOI: 10.1177/1089253207311357</identifier><identifier>PMID: 18270189</identifier><language>eng</language><publisher>Los Angeles, CA: Sage Publications</publisher><subject>Blood Coagulation - drug effects ; Cardiac Surgical Procedures - adverse effects ; Coagulants - administration & dosage ; Coagulants - adverse effects ; Coagulants - economics ; Factor VIIa - administration & dosage ; Factor VIIa - adverse effects ; Factor VIIa - economics ; Humans ; Postoperative Hemorrhage - prevention & control ; Recombinant Proteins - administration & dosage ; Recombinant Proteins - adverse effects ; Recombinant Proteins - economics ; Thrombosis - chemically induced</subject><ispartof>Seminars in cardiothoracic and vascular anesthesia, 2007-12, Vol.11 (4), p.261-264</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c335t-b531f56c64d024fcc3800cec2a7895824df39dad58f5b88dd04fb11cd3b49f453</citedby><cites>FETCH-LOGICAL-c335t-b531f56c64d024fcc3800cec2a7895824df39dad58f5b88dd04fb11cd3b49f453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1089253207311357$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1089253207311357$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18270189$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mazer, C. David</creatorcontrib><creatorcontrib>Leong-Poi, Howard</creatorcontrib><creatorcontrib>Mahoney, James</creatorcontrib><creatorcontrib>Latter, David</creatorcontrib><creatorcontrib>Strauss, Bradley H.</creatorcontrib><creatorcontrib>Teitel, Jerome M.</creatorcontrib><title>Vascular Injury and Thrombotic Potential: A Note of Caution About Recombinant Factor VIIa</title><title>Seminars in cardiothoracic and vascular anesthesia</title><addtitle>Semin Cardiothorac Vasc Anesth</addtitle><description>Postoperative hemorrhage following cardiac surgery increases morbidity, mortality, and costs. Several case reports have described the successful use of recombinant factor VIIa to decrease or stop bleeding in patients undergoing cardiac surgery. The mechanism of action of recombinant factor VIIa is thought to be increased site-specific thrombin generation by tissue factor—mediated activation of coagulation or from activated platelets. However, there have also been many reports of thrombotic complications after recombinant factor VIIa administration. Randomized clinical trials and further laboratory studies should help better clarify the efficacy, safety, cost-effectiveness, and optimal dosing of recombinant factor VIIa in the cardiac surgical setting.</description><subject>Blood Coagulation - drug effects</subject><subject>Cardiac Surgical Procedures - adverse effects</subject><subject>Coagulants - administration & dosage</subject><subject>Coagulants - adverse effects</subject><subject>Coagulants - economics</subject><subject>Factor VIIa - administration & dosage</subject><subject>Factor VIIa - adverse effects</subject><subject>Factor VIIa - economics</subject><subject>Humans</subject><subject>Postoperative Hemorrhage - prevention & control</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Recombinant Proteins - adverse effects</subject><subject>Recombinant Proteins - economics</subject><subject>Thrombosis - chemically induced</subject><issn>1089-2532</issn><issn>1940-5596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1LAzEQhoMotlbvniR_YDWTbLpZb6XYulBUpBY8LfnY6JY2KUn20H_vlhYEwdPM8H7APAjdArkHKIoHIKKknFFSMADGizM0hDInGefl-Lzfezk76AN0FeOaEEoosEs0AEELAqIcos-VjLrbyIArt-7CHktn8PI7-K3yqdX4zafGpVZuHvEEv_QH9hZPZZda7_BE-S7h90b37tZJl_BM6uQDXlWVvEYXVm5ic3OaI_Qxe1pOn7PF67yaThaZZoynTHEGlo_1ODeE5lZrJgjRjaayECUXNDeWlUYaLixXQhhDcqsAtGEqL23O2QiRY68OPsbQ2HoX2q0M-xpIfaBU_6XUR-6OkV2nto35DZyw9IbsaIjyq6nXvguuf-H_wh9O_m6q</recordid><startdate>200712</startdate><enddate>200712</enddate><creator>Mazer, C. David</creator><creator>Leong-Poi, Howard</creator><creator>Mahoney, James</creator><creator>Latter, David</creator><creator>Strauss, Bradley H.</creator><creator>Teitel, Jerome M.</creator><general>Sage Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200712</creationdate><title>Vascular Injury and Thrombotic Potential: A Note of Caution About Recombinant Factor VIIa</title><author>Mazer, C. David ; Leong-Poi, Howard ; Mahoney, James ; Latter, David ; Strauss, Bradley H. ; Teitel, Jerome M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c335t-b531f56c64d024fcc3800cec2a7895824df39dad58f5b88dd04fb11cd3b49f453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Blood Coagulation - drug effects</topic><topic>Cardiac Surgical Procedures - adverse effects</topic><topic>Coagulants - administration & dosage</topic><topic>Coagulants - adverse effects</topic><topic>Coagulants - economics</topic><topic>Factor VIIa - administration & dosage</topic><topic>Factor VIIa - adverse effects</topic><topic>Factor VIIa - economics</topic><topic>Humans</topic><topic>Postoperative Hemorrhage - prevention & control</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Recombinant Proteins - adverse effects</topic><topic>Recombinant Proteins - economics</topic><topic>Thrombosis - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mazer, C. David</creatorcontrib><creatorcontrib>Leong-Poi, Howard</creatorcontrib><creatorcontrib>Mahoney, James</creatorcontrib><creatorcontrib>Latter, David</creatorcontrib><creatorcontrib>Strauss, Bradley H.</creatorcontrib><creatorcontrib>Teitel, Jerome M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Seminars in cardiothoracic and vascular anesthesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mazer, C. David</au><au>Leong-Poi, Howard</au><au>Mahoney, James</au><au>Latter, David</au><au>Strauss, Bradley H.</au><au>Teitel, Jerome M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vascular Injury and Thrombotic Potential: A Note of Caution About Recombinant Factor VIIa</atitle><jtitle>Seminars in cardiothoracic and vascular anesthesia</jtitle><addtitle>Semin Cardiothorac Vasc Anesth</addtitle><date>2007-12</date><risdate>2007</risdate><volume>11</volume><issue>4</issue><spage>261</spage><epage>264</epage><pages>261-264</pages><issn>1089-2532</issn><eissn>1940-5596</eissn><abstract>Postoperative hemorrhage following cardiac surgery increases morbidity, mortality, and costs. Several case reports have described the successful use of recombinant factor VIIa to decrease or stop bleeding in patients undergoing cardiac surgery. The mechanism of action of recombinant factor VIIa is thought to be increased site-specific thrombin generation by tissue factor—mediated activation of coagulation or from activated platelets. However, there have also been many reports of thrombotic complications after recombinant factor VIIa administration. Randomized clinical trials and further laboratory studies should help better clarify the efficacy, safety, cost-effectiveness, and optimal dosing of recombinant factor VIIa in the cardiac surgical setting.</abstract><cop>Los Angeles, CA</cop><pub>Sage Publications</pub><pmid>18270189</pmid><doi>10.1177/1089253207311357</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1089-2532 |
| ispartof | Seminars in cardiothoracic and vascular anesthesia, 2007-12, Vol.11 (4), p.261-264 |
| issn | 1089-2532 1940-5596 |
| language | eng |
| recordid | cdi_crossref_primary_10_1177_1089253207311357 |
| source | MEDLINE; SAGE Journals |
| subjects | Blood Coagulation - drug effects Cardiac Surgical Procedures - adverse effects Coagulants - administration & dosage Coagulants - adverse effects Coagulants - economics Factor VIIa - administration & dosage Factor VIIa - adverse effects Factor VIIa - economics Humans Postoperative Hemorrhage - prevention & control Recombinant Proteins - administration & dosage Recombinant Proteins - adverse effects Recombinant Proteins - economics Thrombosis - chemically induced |
| title | Vascular Injury and Thrombotic Potential: A Note of Caution About Recombinant Factor VIIa |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T17%3A28%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vascular%20Injury%20and%20Thrombotic%20Potential:%20A%20Note%20of%20Caution%20About%20Recombinant%20Factor%20VIIa&rft.jtitle=Seminars%20in%20cardiothoracic%20and%20vascular%20anesthesia&rft.au=Mazer,%20C.%20David&rft.date=2007-12&rft.volume=11&rft.issue=4&rft.spage=261&rft.epage=264&rft.pages=261-264&rft.issn=1089-2532&rft.eissn=1940-5596&rft_id=info:doi/10.1177/1089253207311357&rft_dat=%3Csage_cross%3E10.1177_1089253207311357%3C/sage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/18270189&rft_sage_id=10.1177_1089253207311357&rfr_iscdi=true |